OBTAIN (Outcomes of Beta - Blocker
Therapy After Myocardial Infarction) is an observational multicenter registry in which beta - blocker dosing information was collected in patients with an acute heart attack at participating centers to assess the effect of dose on survival.
Among these studies are studies on more than 19,000 children representing of 47,000 patient years of growth hormone treatment; a prospective study of 100 adult growth hormone — deficient patients followed for 1 to 4 years, a study of 910 children treated with growth hormone for 11 years, a study of 32 adults and children followed for up to 40 years treated with growth hormone (average 10.8 years); a study of 180 growth hormone — treated children followed for over 6 years with reduced cancer recurrence risk (RR 0.6); a prospective analysis of 289 growth hormone — deficient adults who,
after 5 years of growth hormone
therapy, showed lower risk of malignancy (RR 0.25) and decreased risk of
myocardial infarction (RR 0.19) and early mortality (RR 0.22) compared with the untreated group.